Trial Profile

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pilocarpine (Primary)
Indications Presbyopia
Focus Therapeutic Use
Sponsors Orasis Pharmaceuticals

Most Recent Events

12 Apr 2022 According to a media release, the company will present the data from this study at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting, by the Marjan Farid, M.D. and Preeya K. Gupta, M.D..
09 Oct 2019 Status changed from recruiting to completed.
28 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com